Applications of 2,6-Dichloro-7-Methylpurine in Industrial Manufacturing

2,6-Dichloro-7-Methylpurine functions as a key intermediate across multiple advanced chemical sectors. Our direct production supports downstream synthesis in pharmaceutical actives, fine chemicals, crop protection, and nucleoside analogues. Below, we detail its distinct industrial uses with specific process, regulatory, dose, and product insights.

1. Pharmaceutical API Synthesis

Producers employ 2,6-Dichloro-7-Methylpurine as a crucial nucleophilic substrate when building purine-based medicines, notably in the preparation of antineoplastic and antiviral actives. This compound enters in the stepwise alkylation or substitution reactions, serving as the main purine backbone for drugs such as cladribine intermediates. Synthesis demands process qualification under GMP principles and rigorous QA, especially for injectable or oral active pharmaceutical ingredients.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• Ph. Eur. and USP reference standards for nucleoside APIs
• FDA 21 CFR part 211 for finished pharmaceuticals
• Qualified Person (QP) review for importation in the EU

Typical usage ratio

• 0.8–1.1 molar equivalents per API batch; slight excess adjusts for yield optimization

Downstream process integration

• Introduced in Stage 1 or 2 of heterocyclic assembly
• Engages in nucleophilic substitutions using polar aprotic solvents
• Extensive inline HPLC monitoring during process
• Used before final API crystallization and purification

Final product types

• Intermediate blocks for cladribine API
• Other chlorinated purine APIs
• Pharmaceutical active compounds for cytostatic therapies
• Antiviral base molecules and prodrug precursors

2. Agrochemical Intermediate Manufacturing

In the agrochemical sector, this compound provides a purine scaffold for the assembly of selective herbicides and growth regulators. Its halogen substituents facilitate high-yield functionalization, supporting the synthesis of research and commercial batches under industry quality protocols. This segment requires fully traceable supply for environmental and worker safety audits.

Industry compliance standards

• ISO 9001: Quality Management Systems for chemical synthesis
• REACH registration and safety data for Europe
• OECD Principles of Good Laboratory Practice (GLP) for toxicology studies
• EPA regulations for precursors in pesticide synthesis

Typical usage ratio

• 0.5–1.0 equivalent per synthesis—dosed according to structure-activity studies

Downstream process integration

• Used in functionalization phase after initial skeleton construction
• Facilitates N-alkylation routes for active moiety development
• Batch reactor charging under controlled inert atmosphere
• Direct analysis with GC-MS and wet chemistry titrations

Final product types

• Herbicide intermediates (e.g., chlorinated purine derivatives)
• Crop growth regulator actives
• Research compounds for soil treatment trials
• Seed treatment active ingredient scaffolds

3. Fine Chemical Synthesis for Specialty Purines

Chemical and biotech manufacturers use this raw material to construct specialty purine derivatives for chemical biology, enzymology, and analytical standards. The methyl and chloro substituents aid selectivity in advanced multi-step organic syntheses, where high purity and certified batch records are essential for custom molecule development or contract research.

Industry compliance standards

• ISO 9001 and ISO 17025:2017 for laboratory quality and testing
• GMP guidelines for intermediates supplied for regulated research
• Material Safety Data Sheet (MSDS) compliance for lab chemical handling
• Certificate of Analysis (CoA) for each lot

Typical usage ratio

• Adjusted molar ratio (0.9–1.2 equivalents) based on desired purine derivative and side-reaction profile

Downstream process integration

• Incorporated in core ring functionalization, often using Buchwald–Hartwig couplings or SNAr reactions
• Monitored by NMR and LC-MS at each step
• Reaction temperatures tailored from ambient to 120°C
• Purity ensured via preparative chromatography

Final product types

• Purine fluorescent probes for molecular biology
• Reference standards for nucleoside analysis
• Chlorinated nucleobase analogs for research kits
• Custom synthesis tools for drug discovery

4. Nucleoside Analogues Manufacturing

This compound serves as a primary building block for nucleoside analogues employed in pharmacological research and biotechnology applications. Its specific halogenation pattern allows for downstream glycosylation to generate modified nucleosides with targeted properties, often incorporated into next-generation screening libraries and molecular diagnostics.

Industry compliance standards

• Ph. Eur. monograph specifications for research nucleosides
• GMP compliance for nucleoside precursor supply
• ISO/IEC 17025 for analytical method validation of intermediates
• Full traceability from raw material sourcing to delivery

Typical usage ratio

• 1.0 equivalent per nucleoside batch; ratio refined based on glycosylation efficiency and desired analogue yield

Downstream process integration

• Condensed with protected sugars under Lewis acid catalysis
• Applied in batch reactors with moisture exclusion
• Purity and identity verified by HPLC and mass spectrometry at each stage
• Deprotection and crystallization carried out post-glycosylation

Final product types

• Modified nucleoside research chemicals
• Nucleic acid probes for molecular diagnostics
• Sugar-conjugated purine analogues sold to life science labs
• Building blocks for oligonucleotide API synthesis

5. Chemical Genetics and Signal Modulation Compounds

2,6-Dichloro-7-Methylpurine is adopted in chemical biology settings to synthesize purine-based inhibitors and probes for cellular signaling pathways. Its selective substitution pattern makes it particularly effective for assembling small molecule modulators to regulate specific kinases or protein interactions during pathway profiling or drug target validation experiments.

Industry compliance standards

• US OSHA guidelines for laboratory-scale synthesis
• GHS classification for shipment and storage
• Customer-specific material disclosure and CoA for each batch
• ISO 9001 for lot traceability in research chemical supply

Typical usage ratio

• 0.7–1.3 equivalents; determined by inhibitor design and the demand for selectivity over off-targets

Downstream process integration

• Introduced into the synthetic scheme during key derivatization stages
• Transition-metal catalysis or selective alkylation used for kinase inhibitor core assembly
• Integrated into multi-stage laboratory processes with analytical verification after synthesis
• Stock solutions prepared at defined concentrations for screening libraries

Final product types

• PUR analog kinase inhibitors for cell signaling studies
• Chemical genetics tool compounds for pathway modulation
• Bioactive chemical probes sold to research labs
• Lead scaffolds for target-based drug discovery